Home / Market News / $JANX
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Barclays and Wedbush Update Price Targets for Janux Therapeutics

Nov 6, 2026, 10:33 PM UTC · Primary ticker $JANX

Barclays and Wedbush analysts updated their price targets for Janux Therapeutics following the company's third-quarter earnings report. Barclays raised its price target to $15 while maintaining an Underweight rating, and Wedbush increased its target to $40, keeping an Outperform rating. These adjustments reflect revised analyst perspectives on the company's valuation and clinical progress.

This filing discloses that two prominent investment banks, Barclays and Wedbush, have updated their price targets for Janux Therapeutics (JANX) after the company's Q3 earnings report. While both firms increased their price targets, their ratings remain divergent: Barclays maintains an 'Underweight' with a $15 target, and Wedbush an 'Outperform' with a $40 target. This divergence highlights differing analyst opinions on JANX's future prospects and valuation, likely stemming from their interpretation of the Q3 results and clinical pipeline. For traders, this presents a mixed signal; the higher price targets could be seen as positive, but the 'Underweight' rating from Barclays suggests caution. The short-term impact might be limited as these are post-earnings adjustments, but the long-term implications depend on whether JANX can bridge the gap between these disparate valuations through future clinical milestones or financial performance.

$JANX neutral Analyst price target adjustments
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.